Improved blood cellular biocompatibility with heparin coated circuits during cardiopulmonary bypass

被引:0
|
作者
Belboul, A [1 ]
Akbar, O [1 ]
Löfgren, C [1 ]
Jungbeck, M [1 ]
Storm, C [1 ]
Roberts, A [1 ]
机构
[1] Gothenburg Univ, Sahlgrens Univ Hosp, Dept Thorac & Cardiovasc Surg, S-41345 Gothenburg, Sweden
关键词
extracorporeal circulation instrumentation; heparin; cardiopulmonary bypass; cardiac surgical procedures; biocompatible materials;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The clinical use of heparinized surfaces in the extracorporeal circuit was studied to find out if there was any blood cell theologic benefit to support its use in routine low risk cardiac surgery. Methods. In a prospective single blind study, 39 patients were operated upon with the heart lung machine for angina pectoris by coronary bypass grafting and were randomized to a control group or a heparin group. Blood cell rheology was analysed using the St. George filtrometer where damage to the red blood cells and white blood cells was estimated by assessing deformability reductions, transit, time increases and clogging rate and clogging particle changes. Results. At the end of cardiopulmonary bypass, in the heparin group, the red cell filterability (rFR) and the white cell filterability (WFR) were 8% better than in the control group (p = 0.0079 and p = 0.027 respectively). The red cell transit time was 19% slower in the control group (p = 0.0351), The red cell clogging rate (RCR) and clogging particles (RCP) were significantly lower in the heparin group (p = 0.0212 and p = 0.0409 respectively. The white cell clogging rate (WCR) and clogging particles (WCP) showed a similar pattern. Conclusions. In spite of these significant differences the clinical outcome was similar in the groups. Thus heparin coating of the extracorporeal circuit reduces blood cell theologic damage significantly in low risk patients undergoing routine bypass surgery for angina but this use did not lead to any clinical benefit postoperatively. Therefore the use of such circuits for routine low risk cardiac surgery cannot be recommended.
引用
收藏
页码:357 / 362
页数:6
相关论文
共 50 条
  • [31] Clinical use of heparin-coated cardiopulmonary bypass in coronary artery bypass grafting
    Mirow, N
    Minami, K
    KLeikamp, G
    Tenderich, G
    Puhlmann, T
    Körfer, R
    THORACIC AND CARDIOVASCULAR SURGEON, 2001, 49 (03) : 131 - 136
  • [32] The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress
    Sohn, N.
    Marcoux, J.
    Mycyk, T.
    Krahn, J.
    Meng, Q. H.
    PERFUSION-UK, 2009, 24 (04): : 231 - 237
  • [33] Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass
    Nicholson, SC
    Keeling, DM
    Sinclair, ME
    Evans, RD
    BRITISH JOURNAL OF ANAESTHESIA, 2001, 87 (06) : 844 - 847
  • [34] Paraprotein associated heparin resistance during cardiopulmonary bypass
    Khuong, Jacqueline N.
    Forsyth, Cecily J.
    Manuel, Lucy
    Kingsford-Smith, Kate
    Srivastava, Arpit
    Bassin, Levi
    PERFUSION-UK, 2023, 38 (06): : 1319 - 1321
  • [35] Contributing factors to heparin resistance during cardiopulmonary bypass
    Yamashiro, Tomoaki
    Takami, Yoshiyuki
    Takagi, Yasushi
    JOURNAL OF ARTIFICIAL ORGANS, 2024, 27 (04) : 385 - 392
  • [36] Exposure of procoagulant phospholipids on the surface of platelets in patients undergoing cardiopulmonary bypass using non-coated and heparin-coated extracorporeal circuits
    Weerwind, PW
    Caberg, NEH
    Reutelingsperger, CPM
    Lindhout, T
    De Jong, DS
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2002, 25 (08) : 770 - 776
  • [37] Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment
    Fukutomi, M
    Kobayashi, S
    Niwaya, K
    Hamada, Y
    Kitamura, S
    ARTIFICIAL ORGANS, 1996, 20 (07) : 767 - 776
  • [38] A comparative evaluation of the effect of pump type and heparin-coated surfaces on platelets during cardiopulmonary bypass
    Misoph, M
    Babin-Ebell, J
    Schwender, S
    THORACIC AND CARDIOVASCULAR SURGEON, 1997, 45 (06) : 302 - 306
  • [39] Response of the cellular immune system to cardiopulmonary bypass is independent of the applied pump type and of the use of heparin-coated surfaces
    Misoph, M
    Schwender, S
    Babin-Ebell, J
    THORACIC AND CARDIOVASCULAR SURGEON, 1998, 46 (04) : 222 - 227
  • [40] Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia
    Olin, DA
    Urdaneta, F
    Lobato, EB
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2000, 14 (06) : 707 - 709